NCT02815787 - The Drug -Drug Interaction of SP2086 and Glyburide | Biotech Hunter

Enrollment

16

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Type 2 Diabetes

Interventions

DRUG

SP2086

In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.

DRUG

Glyburide

In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.

Trial Locations (1)

250012

Qilu Hospital of Shandong University, Jinan